



Precision Optics for **Space, Defense/Aerospace and Medical Device**

NASDAQ: POCI

Investor Presentation · September 2026

Forward-Looking Statements & Non-GAAP Measures

Forward-Looking Statements

This presentation contains forward-looking statements, including statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements relating to future activities, events or conditions. These statements are based on current expectations, estimates and projections about the Company's business, based in part on assumptions made by management. They are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may differ materially from those expressed or forecast, due to numerous factors, including the risks discussed in the Company's Annual Report on Form 10-K and in other documents the Company files from time to time with the SEC. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after that date, except as required by law.

Non-GAAP Financial Measures

In addition to results reported in accordance with generally accepted accounting principles in the United States ("GAAP"), this presentation includes the non-GAAP financial measure Adjusted EBITDA. Precision Optics defines Adjusted EBITDA as GAAP net income (loss) adjusted to exclude non-recurring transaction costs, depreciation and amortization, non-cash stock-based compensation, interest expense, interest income, and provision (benefit) for income taxes.

The Company uses this measure internally to facilitate period-to-period comparison and analysis of operating performance and liquidity, and believes it is useful to investors as a supplement to GAAP measures. It is not intended as a substitute for measures reported in accordance with GAAP, and may differ from similarly titled measures used by other companies. A reconciliation of net income (loss) to Adjusted EBITDA is provided in the appendix to this presentation and in the Company's quarterly earnings releases filed with the SEC.

Investment Highlights

Record fourth quarter and fiscal year revenue and a second consecutive quarter of positive Adjusted EBITDA

● Revenue Growth

+65%

FY2026 revenue growth, to a record \$31.5 million

● Adjusted EBITDA

\$0.4M

Q4 FY26 Adjusted EBITDA, a second consecutive positive quarter

● Gross Margin

25.3%

Q4 FY26 gross margin, up from 23.6% in Q3 FY26 and 13.0% a year ago

● FY2027 Revenue Guidance

\$30 – \$33M

Revenue guidance, -5 to +5% growth compared to FY2026

● Balance Sheet

\$9.8M

Cash at June 30, 2026

● Franchise Position

Sole-source

Key programs across space, defense/aerospace and medical devices

What Precision Optics Does

Very small, very precise optical systems that let customers see, sense and transmit what they otherwise could not

Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, ultra-high precision and digital imaging technologies across the satellite communications, defense/aerospace and medical device markets, providing services from new product conceptualization through mass manufacture.

- **Founded 1982** — More than four decades of optical design and fabrication experience
- **Two Revenue Engines** — Engineering / product development, and volume Systems Manufacturing
- **Four Operating Units** — Systems Manufacturing, Product Development, Ross Optical, and the MicroOptics Lab
- **Integrated In-House Resources** — Design, machine shop, optics lab, assembly and production under one roof


From concept to mass manufacture

- 1 Customer Requirement**
A visualization or optical challenge with no off-the-shelf answer
- 2 Design & Feasibility**
Optical, mechanical, electrical and systems engineering
- 3 Prototype & Validation**
Build, test, iterate — including regulatory support
- 4 Design for Manufacture**
Processes, tooling, yields and supply chain
- 5 Volume Production**
Repeatable, high-yield manufacturing at scale

The Inflection Point

A transformative year with four consecutive revenue quarters culminating in two consecutive quarters of positive Adjusted EBITDA

Quarterly revenue (\$ millions)



Q4 FY26 Revenue

\$8.8M

vs. \$8.7M in Q3 FY26 and \$6.2M in Q4 FY25

Q4 FY26 Gross margin

25.3%

vs. 23.6% in Q3 FY26 and 13.0% in Q4 FY25

Q4 FY26 Adjusted EBITDA

+\$0.4M

vs. \$0.3M in Q3 FY26 and \$(0.9)M in Q4 FY25

What changed

- **Two large production orders**
Large single-use cystoscope and LEO Satellite Optical Assembly Orders
- **Leadership**
New COO appointed October 2025, new SVP of Sales and Marketing in September 2026
- **Improved Yield**
Aerospace line consistently at 97%, up from 85–95%

Single-use cystoscope consistently at 93%, up from 75-85%
- **Increased Throughput**
Stable, predictable lines after a full operations management update

Capabilities and Markets



Three Differentiated Technology Platforms


The same core competencies serve all three markets



Micro-Optics

Millimeter-sized and smaller cameras and optical assemblies at low manufacturing cost. Proprietary approaches to fabricating opto-mechanical and opto-electronic systems at the industry's smallest sizes.


- Visualization in parts of the body previously inaccessible
- Optical assemblies for space and defense platforms



Multi-Channel & Ultra-High Precision

One of only a handful of companies in the world designing and producing multi-channel endoscopes, as well as laser-based satellite communication modules requiring single digit micron precision manufacturing.

- 4K, fluorescence, AR/VR and 3D minimally invasive surgical imaging systems
- Laser-based satellite communication



Digital Imaging Systems

Full system design for CMOS-based imaging and LED/optical fiber illumination, spanning optical, mechanical, electrical, systems and process engineering — including handheld devices and console capital equipment.


- Complete single-use and reusable medical devices
- Integrated end-to-end visualization systems

Vertically Integrated, Design Through Manufacture

Engineering, machine shop, optics lab and assembly under one roof compresses development time and supports design for manufacturing solutions



Micro-assembly



Optical fiber assembly



Production floor

● Rapid development of new concepts

Ideas move from whiteboard to working hardware without leaving the building

● Design for manufacturability

Producibility is engineered in from the start, not discovered in manufacturing

● Design to production transfer

The same organization that designed the device stands up the production line

● Material sourcing

Ross Optical, a branded division of POC, provides worldwide sourcing and inspection of optical components

● Efficient, high-volume production


Four operating locations across Massachusetts, Maine and Texas

● Quality and regulatory

Including FDA-cleared products already in clinical use

Satellite Communications & LEO/MEO Infrastructure

Managed as a market in its own right — the source of our largest revenue program and, now, a second customer



15–25%

Forecast CAGR range for LEO satellite systems across four independent market studies; the satellite laser communication segment alone is projected to grow from ~\$1.8 billion in 2025 to ~\$5.5 billion by 2030 ¹⁻⁶

Why this market, why now

1

Separated from aerospace

Historically POC has classified space opportunities inside defense/aerospace. Satellite communications is now tracked and resourced as a distinct market with its own drivers and customer set.

2

Optical links enable high inter-satellite bandwidth

Inter-satellite laser links depend on small, high-tolerance optical assemblies that have to be produced repeatably at volume.


3

Already proven in this market

The single largest production program is a sole-source optical assembly for a low earth orbit satellite system, and a second satellite customer signed an initial engineering order in September 2026. POC has supported customer requirements in this area for over five years.

Defense & Aerospace

Optical systems driven relentlessly toward smaller size, weight and power — the SWaP problem we are built for



\$12.7B

Military electro-optical and infrared systems market by 2033, from \$9.0 billion in 2026 at a 4.9% CAGR ¹²

Where we are focused

1

Complex assemblies supporting prime defense contractors

More than five year program with large U.S. defense contractor for highly complex micro opto-mechanical assemblies

2

Jet engine inspection

A recently announced development agreement for a high-end engine inspection borescope operating under demanding performance requirements

3

Directed energy systems

High-precision micro optical components supporting fiber laser systems


4

Expanding go-to-market

Added resources and presence in the segment, including participation at the SPIE Defense + Security conference in April 2026

Medical Device & Single-Use Endoscopy

The market that built the company with ongoing innovation continuing to drive growth



○ Addressed by Precision Optics technology today

What is driving demand

1

Minimally invasive surgery

Procedures keep moving toward smaller access, which requires smaller imaging systems — leveraging POC's micro-optics capability

2

Single-use displacing reusable

Elimination of cross-contamination, better image quality and ease of use are driving the shift — leveraging POC's digital imaging capability

3

Robotic and other next gen surgical procedures

Next-generation procedures require custom imaging devices to interface with customer systems— leveraging POC's design-to-manufacturing capability

10–20%

Forecast CAGR range for the single-use / disposable endoscope market across five independent market studies published 2025–2026

7–11

Our Two Key Production Programs

KEY PROGRAM ONE · SPACE, SATELLITE COMMUNICATIONS

Satellite Optical Assembly

A highly specialized opto-mechanical assembly used to support laser communications in a next-generation satellite platform for a top-tier customer.

\$3.8M

Q4 FY26 record revenue

~\$15MQ4 FY26 Current annualized
run rate**97%**Production yield,
up from 85–95%

- Position** Trusted, strategic sole-source supplier; all indications remain that POC is the sole source for this assembly
- Trajectory** Grew through fiscal 2026 from \$2.7 million in Q1 and Q2 to \$3.6 million in Q3 and a record \$3.8 million in Q4
- Recurring** Satellites in low earth orbit have a limited operating life, so replacements required indefinitely
- Near-term** Customer requested production slowdown in first half of fiscal 2027 while relieving downstream supply chain bottlenecks. Production expected to recover to FY26 levels when customer continues building out their base system.

KEY PROGRAM TWO · MEDICAL, UROLOGY

Single-Use Cystoscope

A single-use cystoscope manufactured in volume for a surgical robotics company, transferred out of engineering and into production in 2024.

\$2.2M

Q4 FY26 record revenue

~\$9MQ4 FY26 Current annualized
run rate**>90%**

Production yield

- Position** Sole external supplier; royalties paid on customer-built units
- Trajectory** Grew from \$1.5 million in Q1 FY2026 to \$2.0 million in Q2 and \$2.2 million in each of Q3 and Q4
- Recurring** Single-use device required for every procedure
- Near-term** Preparing follow-on order for production continuity in FY27.

The Development-to-Production Engine

Engineering programs are the front end of the funnel; each one that converts becomes recurring production revenue

Product development

Customer-funded engineering programs across medical, defense and satellite applications. POC retains ownership/access to intellectual property.

Verification & transfer

Process development, tooling, yield work and regulatory support

Volume production

Recurring revenue typically \$1-3 million per program annually, with operating leverage

9+

Programs in product development pipeline

3–4

Programs in the development pipeline expected to move into production during fiscal 2027

Expanding Product Development Pipeline

Product	Feasibility Study	Prototype Design	Prototype Fabrication	Verification / Validation	Production	Industry	Subsegment	Customer
Multiple Mature "Legacy" Products						Medical Device	Multiple	Multiple
Cystoscope #1						Medical Device	Cystoscopy	Large Medical Device
Opto-Mechanical Assemblies						Space	Satellite Laser Comms	Top-Tier Space
Cardiovascular Endoscope						Medical Device	Cardiac	CardioFocus
Otoscopy Device #1						Medical Device	Otoscopy	Large Medical Device
Micro Optics Components						Defense/Aerospace	Confidential	Top-Tier Defense/Aerospace
Micro Endoscope						Medical Device	Ophthalmology	Mid-Tier Medical Device
Ophthalmoscope #1						Medical Device	Ophthalmology	Large Medical Device
Laparoscope						Medical Device	Robotic Laparoscopy	Well-funded Startup
Ureteroscope						Medical Device	Urology	Mid-Tier Medical Device
Arthroscope #1						Medical Device	Arthroscopy	Mid-Tier Medical Device
ENT Scope						Medical Device	Ear, Nose and Throat	Well-funded Startup
Otoscopy Device #2						Medical Device	Otoscopy	Well-funded Startup
Laparoscope						Medical Device	Laparoscopy	Large Medical Device
Arthroscope						Medical Device	Carpal Tunnel Arthroscopy	Mid-Tier Medical Device
Borescope #2						Defense/Aerospace	Jet Engine Borescope	Top-Tier Defense/Aerospace
Electro-Opto-Mechanical Assembly						Space	Satellite Laser Comms	Top-Tier Space


Financials



Revenue Growth and Fiscal 2026 Results

Revenue by fiscal year (\$ millions)

FY2026 exceeded guidance



\$31.5M

FY2026 revenue, above recent \$29–31M guidance range

+65%


Growth over FY2025 revenue of \$19.1 million

\$(2.1)M


FY2026 Adjusted EBITDA, better than \$(2.5)–(2.7)M recent guidance and an improvement of \$1.6 million over \$(3.7)M in FY2025

Quarterly Revenue, Margin and Adjusted EBITDA


Revenue (\$ millions)



Gross margin (%)



Adjusted EBITDA (\$ millions)



Balance Sheet Highlights and Market Overview

Balance sheet highlights

AT JUNE 30, 2026

Cash and cash equivalents	\$9.8M
Total debt (bank term loans)	\$1.3M
Net cash position	\$8.6M
Accounts receivable, net	\$5.9M
Inventory	\$3.8M
Total assets	\$32.3M
Total current liabilities	\$8.8M
Total shareholders' equity	\$20.3M

Strengthened by an oversubscribed \$11.5 million public offering priced March 27, 2026 at \$3.60 per share, in which the CEO, CFO and COO participated on the same terms as other purchasers.

Market overview

NASDAQ: POCI

Recent share price	\$4.53
Market capitalization	\$50M
52-week range	\$3.55 – \$6.15
Shares outstanding	10,972,792
Options outstanding	1,659,909
Underwriter warrants	159,722
Fully diluted shares	12,792,423

Why Precision Optics, Why Now



1 Inflection Point Achieved

Record revenue of \$31.5 million for fiscal 2026, up 65%, and a second consecutive quarter of positive Adjusted EBITDA.

2 Operating Leverage Is Real

Q4 gross margin reached 25.3% against 13.0% a year earlier, and full-year Adjusted EBITDA improved \$1.6 million to \$(2.1) million.

3 Satellite Is A New Engine

Inter-satellite laser communication links are forecast to grow at a 15–25% CAGR. A second satellite customer signed an initial engineering order in September 2026.

4 Diversification On Schedule

3-4 development programs are expected to enter production in fiscal 2027.

5 Capacity To Invest

\$9.8 million of cash and \$1.3 million of term debt, funding quality, manufacturing engineering, supply chain and go-to-market capability.

6 Management Is Aligned

The CEO, CFO and COO all purchased shares in the March 2026 offering on the same terms as other investors.

Appendix



The Unity Imaging Platform

A modular architecture that turns one-customer, one-device engineering into a repeatable product foundation



Unity flips the traditional model. Instead of designing a device from scratch for every customer, Unity provides a standard baseline CMOS endoscopic system with customization options built on existing or newly designed modular sub-components — a foundation that can serve entire families of products.

Why customers engage

1

Accelerated Time to Market

Customers start from a proven baseline rather than a blank sheet

2

Reduced Development Cost

Shared architecture spreads engineering investment across programs

3

De-Risked Projects

Fewer unknowns at the point where designs transfer to production

Leadership Team

Deep optical expertise paired with operating and public-company financial leadership



Dr. Joseph Forkey

President & Chief Executive Officer

CEO since 2011 and with the Company since 2003, previously as Chief Scientific Officer. Ph.D. in Applied Physics / Mechanical and Aerospace Engineering from Princeton; B.A. in Physics and Mathematics from Cornell; postdoctoral fellow at the University of Pennsylvania Medical School.



Wayne Coll

Chief Financial Officer

More than 30 years of senior financial leadership, primarily in medical device manufacturing. Previously CFO of Flowonix Medical, Micron Solutions, Keystone Dental, Modern Dental Laboratory USA, Pluomed and National Dentex. M.B.A., University of Massachusetts Lowell.



Joseph Traut

Chief Operating Officer

Appointed October 2025 with more than 20 years leading manufacturing, operations and technology transfer in medical device and diagnostics. Previously VP of Operations at T2 Biosystems, VP of Technology Transfer at LumiraDx and VP of Manufacturing Solutions at Ximedica. M.B.A., Bentley University.

Board of Directors

Five directors, four are independent, with medical device, capital markets and technology operating experience

Peter H. Woodward Chairman of the Board <i>Director since 2014</i> Founder of MHW Capital Management, which specializes in significant equity investments in public companies implementing operating strategies to improve profitability. Currently Chairman and Audit Committee Chairman of TSS, Inc. and CEO of Innovative Power. Chartered Financial Analyst; B.A. Colgate, M.I.A. Columbia.	Joseph P. Pellegrino, Jr. Chair, Audit Committee <i>Director since 2025</i> Chief Financial Officer of LeMaitre Vascular, a Nasdaq-listed medical device company, from 2007 until his retirement in 2025, and a continuing member of its board. Previously an investment banking analyst at Lehman Brothers. A.B. Economics, Harvard College; M.B.A., Harvard Business School.	Andrew J. Miclot Chair, Compensation Committee <i>Director since 2016</i> More than 35 years of leadership with medical device suppliers, including Senior Vice President at Symmetry Medical, General Manager and Senior Vice President at ArthroCare, and President and CEO roles at Ascension Orthopedics and Micro Machine Co.	Buell G. Duncan Director <i>Director since 2025</i> Portfolio Advisor and Limited Partner at Iron Gate Capital. Held senior leadership positions across IBM global business units from 1992 to 2020, serving as Chief Marketing Officer of IBM Cloud, Data and AI through 2020.	Dr. Joseph N. Forkey President & Chief Executive Officer <i>Director since 2006</i> Chief Executive Officer, President and Treasurer of Precision Optics since 2011, and a member of the Board since 2006. See the preceding page for full biography.
---	--	--	---	---

Balance Sheet and Capitalization

	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025	6/30/2026
Cash and cash equivalents	\$1,134,697	\$861,650	\$605,749	\$2,925,852	\$405,278	\$1,773,735	\$9,841,142
Accounts receivable, net	1,481,437	1,878,755	2,663,872	3,907,407	3,545,491	4,336,730	5,944,412
Inventory	2,197,244	1,885,395	3,079,938	2,776,216	2,868,100	3,562,112	3,829,414
Total assets	6,351,531	6,261,300	16,704,020	19,740,434	16,912,574	19,790,287	32,335,134
Current liabilities	3,149,380	2,511,110	4,586,641	5,259,620	4,906,816	6,151,294	8,827,941
Acquisition earn-out liability	500,000	333,333	872,559	—	—	—	—
Bank debt (incl. current portion)	—	—	2,328,855	2,689,239	2,175,980	1,867,103	1,289,203
Total shareholders' equity	2,771,761	3,431,127	8,971,495	12,046,592	10,067,788	12,258,834	20,349,312
Shares outstanding*	4,397,263	4,427,492	5,638,363	6,066,518	6,073,939	7,714,701	10,972,792

\$9.8M

Cash at June 30, 2026

\$8.6M

Cash, net of total debt

10,972,792

Common shares outstanding

1,659,909

Options outstanding, wtd. avg. \$4.82

159,722

Underwriter warrants, \$4.21, exp. 2031

*Reflects the 1-for-3 reverse split enacted November 2, 2022. Fiscal year ends June 30.

Income Statement Highlights

(in \$)

	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Q1	Q2	Q3	Q4	FY 2026
Revenues	9,923,356	10,674,907	15,678,248	21,044,467	19,104,349	19,091,269	6,680,823	7,367,837	8,708,631	8,774,474	31,531,765
Cost of Goods Sold	6,560,779	7,241,323	10,750,061	13,310,331	13,306,574	15,686,836	5,734,465	7,163,177	6,652,097	6,550,806	26,100,545
Gross Profit	3,362,576	3,433,584	4,928,187	7,734,136	5,797,775	3,404,433	946,358	204,660	2,056,534	2,223,668	5,431,220
Operating Expenses	4,785,559	4,339,158	6,442,078	8,372,684	8,522,109	8,955,724	2,541,613	1,946,989	2,120,996	2,330,228	8,939,828
Operating Income (Loss)	(1,422,983)	(905,574)	(1,513,891)	(638,548)	(2,724,334)	(5,551,291)	(1,595,255)	(1,742,329)	(64,462)	(106,560)	(3,508,608)
Interest Expense/(Income), Net	(1,001)	(5,302)	(159,538)	(218,927)	(225,108)	(227,019)	(41,775)	(38,462)	(35,116)	(971)	(116,325)
Other Income	—	808,962	745,963	714,798	—	—	—	—	—	—	—
Income Tax	(2,165)	(912)	(952)	(1,936)	(1,936)	(1,936)	—	—	8,705	3,744	(4,958)
Net Income (Loss)	(1,426,149)	(102,826)	(928,418)	(144,613)	(2,949,442)	(5,780,246)	(1,637,030)	(1,780,791)	(108,283)	(103,787)	(3,629,891)
Stock Comp & Services Expense	547,345	733,930	915,494	919,032	959,784	1,612,106	301,639	187,081	253,778	397,193	1,139,692
Business Acquisition Expenses	—	—	162,125	—	—	—	—	—	—	—	—
Other Income	—	(808,962)	(742,052)	(714,798)	—	—	—	—	—	—	—
Depreciation & Amortization	112,218	146,926	190,068	210,735	212,382	212,439	65,181	74,165	75,602	64,329	279,277
Interest Expense/(Income), Net	1,001	5,302	159,538	218,927	225,108	227,019	41,775	38,462	35,116	971	116,325
Income Taxes	2,165	912	952	1,936	1,936	1,936	—	—	8,705	(3,744)	4,958
Adjusted EBITDA	(763,419)	(24,718)	(242,293)	491,219	(1,552,168)	(3,726,746)	(1,228,435)	(1,481,083)	264,918	354,962	(2,089,639)

Some numbers may not total due to rounding.

Sources

SATELLITE COMMUNICATIONS & LEO

- 1 **Fortune Business Insights.** Satellite Mega-Constellations Market. 24.1% CAGR, 2026–34.
- 2 **EIN Presswire.** LEO Satellite Market: USD 30 billion by 2035, 15.5% CAGR.
- 3 **MarketsandMarkets.** Satellite Internet Market. 18.1% CAGR, 2025–30.
- 4 **Research and Markets.** Satellite Internet — Global Strategic Business Report.
- 5 **POCI BD Intelligence Report.** Satellite Laser Communication Systems, 2026. Market ~\$1.8B (2025) to ~\$5.5B (2030), ~25% CAGR.
- 6 **POCI BD Intelligence Addendum.** Commercial Satellite Laser Communications, 2026. Novaspace: 118,000 terminals on orbit by 2035.

MEDICAL DEVICE & ENDOSCOPY

- 7 **Research and Markets.** Disposable Endoscope. 17.0% CAGR, 2024–29.
- 8 **Towards Healthcare.** Disposable Endoscopes Market Sizing. 16.6% CAGR, 2025–35.
- 9 **Grand View Research.** Disposable Endoscopes Market. 12.9% CAGR, 2026–33.
- 10 **MarketsandMarkets.** Disposable Endoscopes. 22.9% CAGR, 2025–30.
- 11 **DelveInsight.** Disposable Endoscopes Market. 10.2% CAGR, 2025–32.

DEFENSE/AEROSPACE & COMPANY

- 12 **Grand View Research.** Military Electro-Optical and Infrared Systems Market, 2026. \$9.0B (2026) to \$12.7B (2033), 4.9% CAGR.